# The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs

> **NCT00354627** · PHASE3 · COMPLETED · sponsor: **Tibotec Pharmaceuticals, Ireland** · enrollment: 5178 (actual)

## Conditions studied

- HIV-1

## Interventions

- **DRUG:** TMC125

## Key facts

- **NCT ID:** NCT00354627
- **Lead sponsor:** Tibotec Pharmaceuticals, Ireland
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2012-02
- **Final completion:** 2012-03
- **Target enrollment:** 5178 (ACTUAL)
- **Last updated:** 2015-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00354627

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00354627, "The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00354627. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*